Global Summit on COVID-19
  • Follow

Accepted Abstracts

Emerging Health Risk of Aspergillosis and Mucormycosis in Covid-19 Patients; A Systematic Review and Meta-analysis

Mehreen Nasir*
King Edward Medical University, Pakistan

Citation: Nasir M (2021) Emerging Health Risk of Aspergillosis and Mucormycosis in Covid-19 Patients; A Systematic Review and Meta-analysis. SciTech Central COVID-19.

Received: November 08, 2021         Accepted: November 11, 2021         Published: November 11, 2021


Background: Fungal infections have increased in number since the onset of this lethal pandemic. The aim of this study is to assess risk factors and case fatality in COVID-19 cases with aspergillosis or mucormycosis.
Methods: Systematic review and meta-analysis was done according to PRISMA guidelines. Data bases used were Google scholar, Pakmedinet, PUBMED and MEDLINE. . The inclusion criteria was original articles and abstracts on aspergillosis or mucormycosis in COVID-19 patients from 1st January 2020 to 15th June, 2021. 2 researchers independently screened the articles of basis of title and abstract. Any discrepancy was solved by discussion.
Results: 21 case reports and case series of mucormycosis in COVID-19 patients were identified and mean age was 56.3 years (36 males and 12 females). The most common comorbidity was diabetes and site was Rhino orbital mucormycosis. Case fatality of 48 combined cases was calculated to be 52%. 19 articles of aspergillosis were included. Diabetes was the most common comorbidity in cases. The number of male cases were more than females. Incidence of aspergillosis in critically sick COVID-19 patients was calculated to be 9.3%. Case fatality was calculated to be 51.2%.
Conclusion: Case fatality from aspergillosis and mucormycosis in Covid-19 cases is quite high. Incidence of aspergillosis in critically sick COVID cases is around 9.2%. Screening can be a beneficial tool for decreasing the morbidity and mortality.
Keywords: COVID-19, Mucormycosis, Aspergillosis